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INTRODUCTION
Reproductive aging is associated with a decline in fertility,
which begins in a moderate and steady fashion starting in the
third to fourth decade but then accelerates rapidly after age
35 (1). A gradual diminution in the pool of ovarian follicles
seems to underlie this decline (2). This age-related decrease
in the follicle number and fertility is marked by an increase
in follicular-phase serum follicle-stimulating hormone (FSH)
levels. This usually starts in women approaching 40 yr of age
(3) and is followed several years later by an increase in luteiniz-
ing hormone (LH) (4, 5). In addition, changes in estradiol (E2)
levels have been described in women with advanced reproduc-
tive age (5).
Various endocrinological markers have been used to assess
the ovarian reserve, and the accurate and reliable determina-
tions of serum ovarian aging marker levels are essential for
safe and successful treatment (6). Previous studies have sug-
gested that anti-Mullerian hormone (AMH) and inhibin B
play important roles as ovarian aging markers (7). AMH is
secreted by granulosa cells of ovarian follicles and appears to
regulate the early follicular development (8). According to a
previous study, serum AMH levels decrease with increasing
age (9). On the other hand, inhibin B is produced by granu-
losa cells which characteristically suppress the synthesis and
secretion of FSH (10). In addition to its role as a FSH mod-
ulator, inhibin B appears to regulate the follicular develop-
ment and promote follicular growth (11).
Other putative intraovarian regulators of follicle growth
include the insulin-like growth factor (IGF) family of pro-
teins. The IGF system is one of several growth factor systems
that probably serve adjunctive roles in ovarian follicle devel-
opment (12). Moreover, IGFs may play an important role in
the human preovulatory process, and IGF-binding proteins
(IGFBPs) may be valuable biochemical markers in the eval-
uation of oocytes maturity (13). IGF-I in blood either circu-
lates freely or is bound to binding proteins, mainly to IGFBP-
3. Furthermore, serum IGFBP-3 levels have been reported
to be positively regulated by IGF-I (14). A small number of
studies have explored the positive relationships between fol-
104
Sun Young Shin*, Jung Ryeol Lee�
Gyung Woon Noh*, Hyun Joo Kim*
Won Jun Kang*,�, Seok Hyun Kim�
June-Key Chung*,�
Department of Nuclear Medicine*, Tumor Immunity
Medical Research Center�; Department of Obstetrics
and Gynecology�, College of Medicine, Seoul National
University, Seoul, Korea
Address for correspondence
June-Key Chung, M.D.
Department of Nuclear Medicine, College of Medicine,
Seoul National University, 28 Yeongeon-dong, 
Jongno-gu, Seoul 110-744, Korea
Tel : +82.2-2072-3376, Fax : +82.2-745-7690
E-mail : jkchung@plaza.snu.ac.kr
J Korean Med Sci 2008; 23: 104-10
ISSN 1011-8934
DOI: 10.3346/jkms.2008.23.1.104
Copyright � The Korean Academy
of Medical Sciences
Analysis of Serum Levels of Anti-Mullerian Hormone, Inhibin B, Insulin-
Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3,
and Follicle-Stimulating Hormone with Respect to Age and
Menopausal Status
This study was undertaken to investigate age-dependent and postmenopausal ch-
anges in the serum levels of anti-Mullerian hormone (AMH), inhibin B, insulin-like
growth factor (IGF)-I, IGF-binding protein-3 (IGFBP-3), and follicle-stimulating hor-
mone (FSH), and to determine which of these markers best reflects the aging pro-
cess in women. A total of 144 women aged 20-59 yr were enrolled in this cross-sec-
tional study. Blood samples were obtained on cycle day 3 of regularly menstruating
women (n=111), or at random in postmenopausal women (n=33). Data were ana-
lyzed with respect to premenopausal women age groups and compared in pre- and
postmenopausal women. Area under the receiver operating characteristic curve
(ROCAUC) analyses were performed to assess the ability of each marker to discrim-
inate between the pre- and postmenopausal status. Serum levels of AMH, IGF-I,
and IGFBP-3 decreased and serum levels of FSH increased significantly with age
in premenopausal women. Serum luteinizing hormone (LH) was higher and inhibin B
was lower in women in their 20-30’s than in 40’s. Serum levels of AMH and IGF-I
showed a consistent decrease with all age groups. ROCAUC analysis showed that
the diagnostic accuracy of AMH for menopausal status was similar to those of FSH,
LH, and inhibin B, and was better than that of IGF-I. In conclusion, the serum AMH
level appears to be the best marker of the aging process in premenopausal women.
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licular fluid IGF-I and ovarian reserve and between follicu-
lar fluid IGF-I and serum IGF-I (5). Although serum IGF-I
levels have been reported to be downregulated in elderly
women and to influence ovarian function (16), the serum
IGF-I level is not widely used as an ovarian aging marker
and its usefulness has not been clearly documented.
The present study was focused on the usefulness of several
ovarian age markers in one population sample with respect
to age and menopausal status. Even though the decreases of
these hormones with age have been reported (7, 9, 16), the
data published to date are not comprehensive enough to reach
a consensus regarding reference ranges. Moreover, no study
has yet been conducted in an Asian population on these hor-
mones. The purposes of this study were to investigate age-
dependent and postmenopausal changes in the serum levels
of AMH, inhibin B, IGF-I, IGFBP-3, and FSH and to iden-
tify which of these markers better reflects the aging process
in Korean women. Furthermore, this study provides diagnos-
tic reference ranges of novel age markers, such as AMH, inhib-
in B, and IGF-I. 
MATERIALS AND METHODS
Subjects
A total of 144 women participated in this study. We recruit-
ed healthy, ovulatory women aged 20-29 yr (n=48), 30-39 yr
(n=33), and 40-49 yr (n=30) and postmenopausal women
aged 50-59 yr (n=33). Premenopausal women were required
to have regular menstrual cycles (24-35 days), and postmeno-
pausal women were required to have been in physiologic me-
nopause for at least 1 yr. No participant had any evidence of
endocrine disorders (normal prolactin and thyroid-stimulat-
ing hormone levels, and no evidence of polycystic ovarian syn-
drome), and all participants were required to have a body mass
index (BMI) of 19-26 kg/m2, both ovaries present, and an
absence of medical or reproductive disorders (including any
history of infertility), and no participant was taking hormone
medications. 
Hormone assays
Blood samples were obtained by venipuncture on cycle day
3 from regularly menstruating women or at random from
postmenopausal women to measure the serum levels of AMH,
inhibin B, IGF-I, IGFBP-3, FSH, LH, and E2. Serum was
separated from blood samples and stored at -20℃ until as-
sayed. Samples from a given subject were analyzed for each
hormone in the same assay to avoid inter-assay variation.
Serum levels of LH and FSH were measured by immuno-
radiometric assay (IRMA) using commercial kits (Biosource,
Nivelles, Belgium). The detection limits of the assay were
0.2 mIU/mL for LH and 0.1 mIU/mL for FSH. Intra- and
inter-assay coefficients of variation (CV) were 3.2% and 6.7%
for LH, and 3.3% and 7.1% for FSH, respectively. Samples
were analyzed for E2 using radioimmunoassay (RIA) using
commercial kits (Biosource, Nivelles, Belgium). The detec-
tion limit of this assay was 10 pg/mL, and intra- and inter-
assay CVs were 4.9% and 5.2%, respectively. Serum levels
of IGF-I and IGFBP-3 were determined by IRMA using
reagents supplied by Diagnostic Systems Laboratories (DSL
Inc., Webster, U.S.A.). Its detection limits were 2.06 ng/mL
for IGF-I and 0.5 ng/mL for IGFBP-3, and its intra- and
inter-assay CVs were 5.1% and 9.1% for IGF-I, and 5.2%
and 7.1% for IGFBP-3, respectively.
Serum levels of AMH and Inhibin B were determined
using enzyme-linked immunosorbent assays (ELISA) using
commercial kits from Diagnostic Systems Laboratories (DSL
Inc., Webster, U.S.A.). The detection limits of this assay were
0.017 ng/mL for AMH and 7 pg/mL for Inhibin B, and its
intra- and inter-assay CVs were 4.6% and 8.0% for AMH
and 5.6% and 7.6% for inhibin B, respectively.
Statistical analysis
Data were analyzed by age group in premenopausal women.
Differences between age groups were tested by one-way anal-
ysis of variance (ANOVA), followed by Turkey’s multiple com-
parison test. Comparisons between pre- and postmenopausal
women were made using Mann-Whitney U test. The abilities
of hormone levels to discriminate between pre- and postme-
nopause women were investigated using receiver operating
characteristic (ROC) analysis. The diagnostic values of the
various hormone markers were evaluated by comparing areas
under the curves (ROCAUC) (23). Statistical analyses were per-
formed using SPSS 12.0 for Windows (SPSS Inc., Chicago,
IL, U.S.A.), and p values of <0.05 were considered statisti-
cally significant. We drew fitting plots of hormone levels
versus age. Mean data values with error bar are presented in
the fitting plots. The x-axis was divided into intervals of 5 yr
and each curve was fitted using linear, Gaussian, Lorentzian,
and sigmoid functions using Mathematica 5.0 (Wolfram
Research Inc., Champaign, IL, U.S.A.)
RESULTS
The characteristics of the premenopausal subjects and their
serum hormone levels on cycle day 3 are shown in Table 1.
Serum levels of AMH, IGF-I, and IGFBP-3 decreased and
those of FSH increased significantly with age. Serum levels
of E2, LH, and inhibin B showed no significant differences.
However, serum LH was higher and inhibin B was lower in
women in their 20-30’s than in 40’s. AMH and IGF-I levels
consistently decreased with age, and showed significant changes
across all ages, whereas IGFBP-3 and FSH levels showed a
significant difference only between women in their 30’s and
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40’s. 
Median ages and serum hormone levels of premenopausal
and postmenopausal women are presented in Table 2. Data
for AMH and inhibin B were not normally distributed in the
postmenopausal women, mainly because the majority of val-
ues were below the detection limit. Hence the data were pre-
sented as medians and ranges, and a nonparametric method
was used for comparison between two groups. Premenopausal
and postmenopausal women had median ages of 31 (range
20-49) yr and 56 (range 50-59) yr, respectively. Serum levels
of LH, FSH, E2, IGF-I, AMH, and inhibin B showed signif-
icant differences between pre- and postmenopausal women
(p<0.001). However, serum IGFBP-3 levels did not change
significantly after menopause. As expected, LH and FSH lev-
els in postmenopausal women were significantly higher and
those of E2, IGF-I, AMH and inhibin B levels were signifi-
cantly lower than in premenopausal women. 
AMH was undetectable in 20 of 33 postmenopausal wo-
men, whereas it was only undetectable in 2 of 111 premeno-
pausal women. Inhibin B was undetectable in all postmeno-
pausal women and in 10 of 111 premenopausal women;
moreover, these 10 women were older than 40 yr old. 
Serum levels of AMH and IGF-I showed linear decreases
from the earlier age (Fig. 1A, B), whereas FSH and LH levels
showed sigmoid increases and showed greatest increase after
menopause (Fig. 1C, D). Serum E2 levels were fitted using
sigmoid and Lorentzian functions (Fig. 1E) and inhibin-B
levels showed a sigmoid decrease (Fig. 1F), and both of these
hormones decreased after menopause. Serum IGFBP-3 levels
were fitted using Gaussian function with a minimum value
at the boundary between pre- and postmenopause (Fig. 1G).
Table 3 shows the results of ROC curve analysis for serum
markers. This analysis showed that the diagnostic accuracy of
AMH (ROCAUC=0.943) for menopausal status was similar to
those of FSH (ROCAUC=0.998), LH (ROCAUC=0.996), and inhi-
bin B (ROCAUC=0.945), and was better than IGF-I (ROCAUC=
0.875). Cutoff levels providing desired sensitivities and speci-
ficities can be deduced from ROC curves. When the point on
a curve closest to the upper left corner of the box correspond-
ing to 100% sensitivity and 100% specificity (0% false posi-
tivity) was selected, it resulted in cutoff levels for AMH of
<0.46 ng/mL and for inhibin B of <0.4 pg/mL in terms of
identifying postmenopausal subjects. The sensitivity and speci-
ficity corresponding to these cutoffs were 92% and 97% for
AMH, and 91% and 100% for inhibin B, respectively, and
the cutoff level of IGF-I was <231.5 ng/mL with a sensitiv-
ity and specificity of 90% and 76%, respectively. The sensi-
tivity and specificity of AMH were similar to those of FSH,
Age groups 20-29 (n=48) 30-39 (n=33) 40-49 (n=30) p value*
Age (yr) 25.2±2.8 34.2±3.1 44.0±2.7 <0.001
LH (mIU/mL) 3.4±2.4 3.6±1.4 3.2±1.6 0.653
FSH (mIU/mL)� 4.3±1.4a 5.9±2.4a 8.9±5.8b <0.001
Estradiol (pg/mL) 51.3±19.4 50.1±16.7 60.7±30.2 0.119
IGF-I (ng/mL)� 463.8±111.4a 347.3±105.7b 263.7±70.8c <0.001
IGFBP-3 (ng/mL)� 4,495.1±6,38.9a 4,348.2±703.9a 3,965.9±631.0b 0.003
AMH (ng/mL)� 4.8±3.0a 2.8±2.2b 1.2±1.2c <0.001
Inhibin B (pg/mL) 52.2±39.1 52.0±37.9 36.9±35.1 0.175
Table 1. Characteristics of study subjects and serum marker levels in premenopausal women by age
LH, luteinizing hormone; FSH, follicle-stimulating hormone; IGF-I, insulin-like growth factor-I; IGFBP-3, IGF-binding protein-3; AMH, anti-Mullerian hormone.
Values are means±S.D..
*By ANOVA; �Same letters indicate non-significant differences between groups as determined by Turkey’s multiple comparison test.
LH, luteinizing hormone; FSH, follicle-stimulating hormone; IGF-I, insulin-
like growth factor-I; IGFBP-3, IGF-binding protein-3; AMH, anti-Mullerian
hormone; MP, menopause; ND, non-detectable.
Values are medians (range).
Pre-MP (n=111) Post-MP (n=33) p value
Age (yr) 31 (20-49) 56 (50-59) <0.001
LH (mIU/mL) 3.1 (0.8-14.1) 15.8 (6.8-55.9) <0.001
FSH (mIU/mL) 5.0 (1.6-29.2) 51.9 (11.3-116) <0.001
Estradiol (pg/mL) 49 (17-140) 20 (12-36) <0.001
IGF-I (ng/mL) 363 (87-767) 179 (35-388) <0.001
IGFBP-3 (ng/mL) 4,254 (2,796-6,071) 4,070 (2,539-6,301) 0.141
AMH (ng/mL) 2.54 (ND-12.2) ND (ND-0.80) <0.001
Inhibin B (pg/mL) 44.2 (ND-189) All ND <0.001
Table 2. Age and marker levels according to the menopausal
status
LH, luteinizing hormone; FSH, follicle-stimulating hormone; IGF-I, insulin-
like growth factor-I; IGFBP-3, IGF-binding protein-3; AMH, anti-Mullerian
hormone.
ROCAUC, area under the receiver operating characteristic curve.
Cut-off
% Sen-
sitivity
% Spe-
cificity
p
value
ROCAUC
LH 0.996 >8.7 mIU/mL 98.2 97.0 <0.001
FSH 0.998 >22.3 mIU/mL 99.1 97.0 <0.001
Estradiol 0.954 <34.5 pg/mL 83.8 97.0 <0.001
IGF-I 0.875 <231.5 ng/mL 90.1 75.8 <0.001
IGFBP-3 0.584 <4168.0 ng/mL 59.5 54.5 0.141
AMH 0.973 <0.5 ng/mL 91.9 97.0 <0.001
Inhibin B 0.955 <0.4 pg/mL 91.0 100 <0.001
Table 3. Receiver operating characteristic curve analysis results
for serum markers in terms of discriminating menopausal status
. .
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LH, and inhibin B, and were better than those of IGF-I. 
DISCUSSION
Several studies have investigated changes in markers of
ovarian follicular reserve. Serum FSH levels increase in old
reproductive age women, a fact that has been well document-
ed and recognized for many years by many investigators (5).
In women approaching 40 yr of age, serum FSH levels usu-
ally begin to rise, which reflects a reduction in the number
of early antral follicles present that can be recruited to ovu-
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Fig. 1. Fitting plots of hormone serum levels according to age. (A)
AMH, y=8.438-0.156x; (B) IGF-I, y=667-8.69x; (C) FSH, y=62.8-
58.2 Exp[-(x-50)/2]/(1+Exp[-(x-50)/2]); (D) LH, y=21.0-18.2 Exp[-
(x-50)/2]/(1+Exp[-(x-50)/2]); (E) E2, y=0.27+45.6 Exp[-(x-50)/2]/
(1+Exp[-(x-50)/2])+23.2/(1+(x-50)2/100); (F) Inhibin B, y=-13.4+
65.3 Exp[-(x-50)/4]/(1+Exp[-(x-50)/4]); (G) IGFBP-3, y=4540.4-
569.66 Exp[-(x-50)2/250].
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late (3). Serum FSH levels increase over time because inhib-
in B and E2 production are reduced by a diminished cohort
of growing follicles (18, 19). Nevertheless, prior to age 40,
FSH levels are not correlated with age, which confirms the
lack of correlation between FSH and age in women aged 20-
35 (20, 21). However, the proper assessment of ovarian aging
at an early stage is crucial in terms of counseling patients
about their possibility of pregnancy, either spontaneously or
during fertility therapy. Therefore, a new marker of ovarian
aging in younger women is needed.
Previous studies have reported that serum AMH levels are
closely related to the early antral follicle count, and moreover,
this relationship was found to be remarkably more strong than
those of inhibin B, E2, FSH, or LH (8, 9, 22). The serum AMH
level decreased with ages in premenopausal women and post-
menopausal women, which is in line with the findings of de
Vet et al. (7). In the present study, it was found that serum
AMH levels in normal ovulatory women reduced with advanc-
ing age before changes in other markers (e.g., FSH and inhib-
in B) were apparent, and that AMH was undetectable in most
of postmenopausal women. These results are in line with those
of previous studies and suggest that AMH could be used as
a novel marker of ovarian aging.
Age-dependent decreases of IGF-I may occur secondary to
age-dependent reductions in growth hormone secretion (23,
24). IGF-I has been shown to serve as an intraovarian regula-
tor of follicle function in rodents and to exerts a direct effects
on human and rodent granulos a cell function (25, 26). More-
over, IGF-I, in conjunction with gonadotropins, appears to
promote follicle growth (27) and steroid secretion (28) and
to act as an antiatretic hormone (29). Although serum IGF-
I levels have been reported to be attenuated in elderly women
(16) and follicular fluid IGF-I levels have been demonstrat-
ed to be related to the ovarian reserve (15), serum IGF-I lev-
els are not widely used as an ovarian aging marker and the
usefulness of serum IGF-I has not been clearly documented
in this context. Based on a high correlation between serum
and follicular fluid levels of IGF-I and on the positive corre-
lation between follicular fluid level and an ovarian reserve
(15), it can be speculated that serum IGF-I and ovarian reserve
are positively correlated. The present study demonstrates age-
dependent and postmenopausal changes in the serum levels
of IGF-I, which suggests that serum IGF-I is an another can-
didate marker of ovarian reserve.
The results of the present study indicate that serum levels
of AMH, IGF-I, and IGFBP-3 decrease and that those of
FSH increase significantly with age in premenopausal women,
but serum levels of inhibin B do not decrease significantly
with age. In addition, FSH levels in normal ovulatory women
in their 20’s and 30’s were similar, which is in line with pre-
vious reports on inhibin B and FSH (7, 20, 21). In contrast,
serum levels of AMH and IGF-I were significantly different
in women in these age groups. It is noteworthy that serum
levels of AMH and IGF-I significantly changed at earlier
ages than did those of the other hormones in premenopausal
women; moreover, the main limitation of conventional ovari-
an reserve markers such as FSH, LH, and E2 is that their
serum levels change relatively late.
All hormones examined showed significant differences pre-
to postmenopause except IGFBP-3. Inhibin B was practi-
cally undetectable after menopause, and AMH was unde-
tectable in 20 of the 33 postmenopausal women. This is
supposed to be because inhibin B and AMH are produced
by the granulosa cells of ovarian follicles (7, 10). Several stud-
ies have investigated changes in AMH and inhibin B, and
also found that they ultimately become undetectable after
menopause (7, 30). 
To follow the age-dependent changes of each marker more
precisely, we fitted their hormone level versus age plots. After
menopause, serum FSH and LH levels increase markedly
and E2 and inhibin B levels decrease markedly, but no changes
in these markers were observed during earlier premenopausal
ages. The fitting curves of the AMH and IGF-I serum levels
versus ages showed a linear decrease from the earlier age. The
present study more precisely characterized the usefulness of
AMH and IGF-I during early reproductive ages. These results
suggest that AMH and IGF-I are better markers of ovarian
reserve in premenopausal women than other hormone mark-
ers, such as FSH, LH, E2, and inhibin B. 
To determine whether AMH or IGF-I better reflects the
aging process in women, we compared the diagnostic accu-
racies of hormone levels in terms of differentiating between
pre- and postmenopausal status (Fig. 2). ROCAUC analysis
showed that the diagnostic accuracy of AMH for menopausal
status was similar to those of FSH, LH, E2, and inhibin B, and
that it was better than IGF-I. The reason for the inferiority of
IGF-I to AMH and other markers appears to be that IGF-I
Fig. 2. Receiver operating characteristic curves of serum AMH
and IGF-I levels on cycle day 3 for differentiating between pre-
menopausal and postmenopausal women.
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levels decrease continuously after menopause, whereas FSH,
LH, and E2 levels are fairly stable and AMH and inhibin B
levels vanish after menopause.
In conclusion, the present study provides strong evidences
that the serum AMH level is an important marker of repro-
ductive aging in women. It was also found that serum IGF-I
is a good candidate ovarian aging marker, especially in pre-
menopausal women. In addition, the results of this study
provide useful reference data of serum AMH ranges in Kore-
an populations. Further research of large scale and longitudi-
nal design is necessary to confirm our results. 
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